Janux Therapeutics To Host Virtual Event On Monday, December 2, 2024, At 4:30 PM ET Discussing Updated Clinical Data In Phase 1a Dose Escalation For JANX007 In MCRPC And Doses Selected For Phase 1b Expansion Studies

Benzinga · Nov 25 22:03

The virtual event will take place on Monday, December 2, 2024, at 4:30 PM ET

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced it will host a virtual event on Monday, December 2, 2024, at 4:30 PM ET.

David Campbell, Ph.D., President & Chief Executive Officer, will provide an update on JANX007 Phase 1a dose escalation data and doses selected for Phase 1b expansion studies in adult subjects with metastatic castration-resistant prostate cancer (mCRPC).

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Janux Therapeutics To Host Virtual Event On Monday, December 2, 2024, At 4:30 PM ET Discussing Updated Clinical Data In Phase 1a Dose Escalation For JANX007 In MCRPC And Doses Selected For Phase 1b Expansion Studies

Risk Disclaimer